PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
3.69%
Cash & equivalents growing 3.69% while Medical - Pharmaceuticals shows decline of -0.49%. Warren Buffett would see this as a competitive advantage in maintaining liquidity while peers face cash constraints.
100.00%
Short-term investments yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt might see stronger near-cash accumulation as an opportunity. Check yields vs. peers.
3.69%
Below half the Medical - Pharmaceuticals median of -0.92% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
4.55%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
0.14%
Inventory growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
47.44%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
2.53%
Current assets growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a potential liquidity edge if well allocated.
2.03%
PP&E growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.17%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
15.35%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
15.35%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
12.51%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
-6668.56%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
985.79%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
1.86%
≥ 1.5x the Medical - Pharmaceuticals median of 0.09%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
2.08%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
5.13%
Payables growth above 1.5x Medical - Pharmaceuticals median of 2.95%. Jim Chanos might see a warning sign of stressed supplier payments.
No Data
No Data available this quarter, please select a different quarter.
-58.46%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-83.72%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
285.15%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
1.97%
Above 1.5x Medical - Pharmaceuticals median of 0.63%. Jim Chanos suspects potential working capital strain.
-9.54%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
118.99%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-7.06%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
0.71%
Below half Medical - Pharmaceuticals median of -0.44%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
4.43%
Below half Medical - Pharmaceuticals median of -3.11%. Jim Chanos suspects poor profitability or large dividend drains.
5.56%
1.25-1.5x Medical - Pharmaceuticals median 3.92%. Guy Spier is cautious about bigger AOCI expansions.
No Data
No Data available this quarter, please select a different quarter.
4.03%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees stronger equity growth vs. peers.
2.08%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees more aggressive expansions than peers.
433425.00%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
-30.60%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-129.06%
Above 1.5x Medical - Pharmaceuticals median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.